Figure 3 Survival rates for FGL2 in breast cancer. The GEPIA database, PrognoScan database, and Kaplan-Meier plotter database were used to analyze the prognostic potential of FGL2 in breast cancer. (A) In the GEPIA database, a lower expression level of FGL2 was associated with a poor prognosis of disease-free survival (DFS) in breast cancer. (B–F) In the PrognoScan database, GSE9893, GSE3494, GSE4922, GSE2034, and GSE19615 were used to evaluate overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), and distant metastasis-free survival (DMFS), respectively. (G–I) The Kaplan-Meier plotter database was used to measure OS, relapse-free survival (RFS), and DMFS related to FGL2 in breast cancer.